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Between 1979 and 1984, 321 patients received 354 St. Jude Medical 
prostheses (194 aortic, 94 mitral, 1 tricuspid, and 32 multiple valve 
replacements). Follow-up was 96% complete (2967 patient-years; mean 9.5 
years per patient). Actuarial event-free rates at 10 years and linearized 
rates (in parentheses) of late complications were as follows: embolism, 
85.0% - 2.3% (2.3% per patient-year); anticoagulant-related hemorrhage, 
74.8% - 2.7% (3.3% per patient-year); cerebrovascular ccident, 81.8% -+ 
2.5% (2.6% per patient-year); prosthesis thrombosis, 98.5% - 0.7% (0.1% 
per patient-year); endocarditis, 97.2% - 1.1% (0.4% per patient-year); 
prosthesis dysfunction, 97.1% -+ 1.0% (0.4% per patient-year); hemolytic 
anemia, 98.5% -+ 0.7% (0.1% per patient-year); reoperation, 97.4% + 1.0% 
(0.4% per patient-year); overall mortality, 63.3% - 2.7% (4.2% per patient- 
year); and valve-related death (including sudden death), 84.7% -+ 2.2% 
(1.4% per patient-year). Independent preoperative risk factors were as 
follows: (1) for embolism, cardiac failure as indication for operation and 
history of prior systemic embolism; (2) for cerebrovascular ccidents, the 
same two factors and age; (3) for endocarditis, diabetes, chronic alcohol- 
ism, and aortic valve replacement; (4) for overall mortality, age, ejection 
fraction (or cardiac index or cardiothoracic index), chronic alcoholism, and 
history of systemic embolism; and (5) for valve-related death, c ronic 
alcoholism, degenerative cause of valve disease, and prosthetic diameter 23 
mm or smaller. Ninety percent of survivors were in New York Heart 
Association functional class I or II at the end of follow-up. In conclusion, 
this study confirms the excellent durability of the St. Jude Medical valve 
and the remarkable functional benefit for the majority of the patients. 
However, prosthesis-related complications are still common, particularly 
for small-diameter p ostheses. Outcome is strongly related to the patient's 
preoperative cardiac condition and to the adequacy of anticoagulation 
control. (J Thorac Cardiovasc Surg 1997;113:134-48) 
T he St. Jude Medical valve is a bileaflet, low- profile, central flow design prosthesis known for 
its excellent hemodynamic properties. Follow-up 
studies have also demonstrated its mechanical du- 
rability, 1-18 and only anecdotal structural failures 
have been reported. 2'19, 2o Nevertheless, these stud- 
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ies have also shown that, despite a thromboresistant 
pyrolytic arbon coating, anticoagulant therapy with 
its related risks is still required. In the present study, 
the incidence and preoperative determinants of 
every late complication are analyzed in patients 
followed up at least 10 years after the implantation 
of a St. Jude Medical prosthesis. Analysis of early 
events is also briefly presented. 
Patients and methods 
Patients. Between July 1979 and December 1984, 519 
patients received at least one St. Jude Medical valve in our 
hospital. To get the most complete follow-up we only 
selected for study the patients living in Switzerland at the 
time of operation. Thus 321 patients were included who 
received 354 St. Jude Medical valves. Clinical data are 
shown in Table I. Previous valve operation had been done 
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Table I. Patient data (n = 321) 
AVR MVR TVR Multiple VR All 
No. of patients 194 94 1 32 321 
Age (mean -+ SD) 58 -+ 13 57 -+ 11 68 52 _+ 14 57 + 13 
Sex 
Male 132 (68.0%) 41 (43.6%) - -  16 (50.0%) 189 (58.9%) 
Female 62 (32.0%) 53 (56.4%) 1 16 (50.0%) 132 (41.1%) 
NYHA class 
I 17 (8.8%) 2 (2.1%) - -  1 (3.1%) 20 (6.2%) 
II 75 (38.7%) 29 (30.9%) 1 12 (37.5%) 117 (36.5%) 
III 68 (35.0%) 47 (50.0%) - -  15 (46.9%) 130 (40.5%) 
IV 34 (17.5%) 16 (17.0%) - -  4 (12.5%) 54 (16.8%) 
Rhythm ECG 
Sinusal 174 (89.7%) 33 (35.1%) 1 13 (40.6%) 221 (68.8%) 
AF 18 (9.3%) 60 (63.8%) - -  18 (56.3%) 96 (30.0%) 
Other 2 (1.0%) 1 (1.1%) - -  1 (3.1%) 4 (1.2%) 
CAD 
Present 36 (18.6%) 10 (10.6%) - -  4 (12.5%) 50 (15.6%) 
Abseht 137 (70.6%) 77 (81.9%) 1 26 (81.3%) 241 (75.1%) 
Unknown 21 (10.8%) 7 (7.5%) - -  2 (6.2%) 30 (9.3%) 
History of embolism 15 (7.7%) 7 (7.5%) - -  1 (3.1%) 23 (7.2%) 
Cardiothoracic index 0.54 -+ 0.06 0.56 -+ 0.07 0.76 0.56 -+ 0.05 0.55 -+ 0.07 
(mean _+ SD) 
Emergency operation 8 (4.1%) 6 (6.4%) - -  - -  14 (4.3%) 
TVR, Tricuspid valve replacement; SD,standard deviation; ECG, electrocardiogram; AF, atriai fibrillation; CAD, coronary artery disease. 
in 34 patients (11%) and coronary artery bypass grafting 
in 2 patients (0.6%). The characteristics of the pathologic 
valves are shown in Table II. Hemodynamic and angio- 
graphic preoperative data for aortic or mitral valvulopathy 
are shown in Table III. The first indication for operation 
was cardiac failure in 226 cases (70.4%), chest pain in 16 
(5%), syncope in 20 (6.2%), prosthesis dysfunction i  8 
(2.5%), recurrent emboli n 1 (0.3%), and combination of
two symptoms or more in 50 (15.0%). 
Surgical procedures. Operations were done with use of 
the standard technique of cardiopulmonary b pass with 
moderate hypothermia (28 ° to 32 ° C) and cold crystalloid 
cardioplegia combined with topical cooling. Aortic St. 
Jude Medical prostheses were inserted with the pivot 
perpendicular to the interventricular septum whereas 
most mitral valves were placed in the anatomic position, 
with use of a semiinterrupted running suture technique 
with Prolene 2-0 polypropylene sutures. Preservation of 
posterior mitral eaflet was not realized at the time these 
operations were done. Combined coronary artery bypass 
grafting with saphenous vein was done in 44 cases (14%). 
Additional procedures and diameters of St. Jude Medical 
valves used are shown in Table IV. 
Antieoagulation. I travenous heparin anticoagulation 
therapy was started on the first postoperative day and 
continued until the prothrombin time (PT) could be 
regulated by daily warfarin administration. The recom- 
mended anticoagulation level was a PT of 15% to 25% 
(corresponding international normalized ratio [INR], 3 to 
4.5). After hospital discharge, the referring physician was 
in charge of the anticoagulation control. 
Follow-up. One-time follow-up data were obtained by 
questionnaires addressed to the physicians in charge of 
the patients (response rate 93%) and by telephone inter- 
Table II. Characteristics o f  pathologic valves 
(n = 354) 
Aortic Mitral Tricuspid 
(n = 226) (n = 126) (n = 2) 
Dysfunction 
Stenosis 55 (24.4%) 20 (15.9%) 
Regurgitation 76 (33.6%) 55 (43.7%) 
Mixed 95 (42.0%) 51 (40.4%) 
Etiology 
Rheumatic 53 (23.5%) 48 (38.0%) 
Congenital 97 (42.9%) - -  
Myxomatous 12 (5.3%) 48 (38.0%) 
Endocarditic 26 (11.5%) 18 (14.3%) 
Degenerative (calcific) 17 (7.5%) 1 (0.8%) 
Prosthetic dysfunction 6 (2.7%) 2 (1.6%) 
Ischemic - -  3 (2.4%) 
Other causes 10 (4.4%) 1 (0.8%) 
Unknown 5 (2.2%) 5 (4.0%) 
view with all living patients or the patient's family in case 
of death; further information about complications was 
obtained from hospital reports. Death certificates were 
reviewed for each case of sudden death or death from 
unknown cause. Fourteen patients were lost to follow-up; 
follow-up was thus 96% complete and represented 2967 
patient-years with a mean of 9.5 years per patient, a 
median of 10.8 years, and a maximum of 15.6 years. 
Definitions. We used the guidelines of The Society of 
Thoracic Surgeons and The American Association for 
Thoracic Surgery 21 for the definitions of morbid events 
and mortality and the recommendations of Bodnar and 
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Table I I I .  Hemodynamic and angiographic preoperative data (for single valvulopathy only) 
Maximum 
Cardiac index EF MPAP PWP LVEDI LVESI Valve surface gradient 
(L/min/m z) (%) (mm Hg) (mm Hg) (ml/m 2) (ml/m 2) (cm 2) (mm Hg) 
Aortic pathology 
Stenosis (n = 50) 2.69 -+ 0.71 68 _+ 18 23 _+ 9 15 _+ 7 93 -+ 46 37 _+ 18 0.58 _+ 0.22 75 + 28 
Regurgitation ( = 56) 2.69 _+ 0.69 59 + 15 22 _+ 8 15 _+ 7 158 - 50 69 _+ 40 
Mixed stenosis and regurgi- 2.58 _+ 0.76 65 + 14 26 _+ 14 18 _+ 10 108 _+ 39 41 _+ 29 0.73 _+ 0.40 69 _+ 31 
tation (n = 88) 
Mitral pathology 
Stenosis (n = 14) 2.22 _+ 0.52 73 -+ 10 30 _+ 9 23 _+ 6 89 _+ 18 26 _+ 8 0.88 + 0.26 15 _+ 5 
Regurgitation ( = 49) 2.22 _+ 0.54 64 _+ 14 30 _+ 12 21 _+ 9 139 _+ 50 53 _+ 34 
Mixed stenosis and regurgi- 2.08 ± 0.38 66 _+ 11 32 _+ 14 23 _+ 8 92 _+ 28 33 -+ 18 1.28 _+ 0.60 15 -+ 5 
tation (n = 31) 
Results are indicated as mean plus or minus tandard deviation. EF, Ejection fraction; MPAP, mean pulmonary arterial pressure; PWP, pulmonary wedge 
pressure; LVEDI,, left ventricular end-diastolic index; LVESI, left ventricular end-systolic index. 
Table IV. Surgicalprocedures 
Valve size (mm) No. 
Valve position 
Aortic 
Mitral 
Tricuspid 
19 2 
21 12 
23 44 
25 58 
27 62 
29 36 
31 12 
27 3 
29 15 
31 94 
33 14 
23 1 
31 1 
Additional operative procedures 
Coronary artery bypass grafting 44 
Aortic root replacement 6 
Tricuspid annuloplasty 3 
Other 7 
colleagues 22to report thrombosis, embolism, and bleed- 
ing. We present he incidence of emboli according to the 
criteria of McGoon)  3 Some review of the precise terms 
used is helpful: hemorrhages referred to any episodes that 
necessitated hospital care (inpatient or outpatient care) 
for diagnostic or therapeutic nterventions and to episodes 
that led to death. Ischemic erebrovascular accidents were 
classified as follows: (1) transient ischemic attack: focal 
neurologic signs of vascular origin lasting less than 24 
hours; (2) reversible neurologic deficit: neurologic deficit 
lasting more than 24 hours but resolving before hospital 
discharge; (3) major stroke: neurologic defects still 
present at hospital discharge; and (4) fatal stroke. Valve- 
related hemolytic anemia was defined as the presence of 
normocytic normochromic anemia (hemoglobin value 
<13 gin/100 ml for men, <12 gm/100 ml for women) with 
a lactate dehydrogenase elevation and/or a haptoglobin 
decrease and/or schistocytes, in the absence of any other 
known cause. Sudden death was defined as a nonacciden- 
tal, witnessed or unwitnessed death of a person for whom 
time and mode of death were unexpected. Anticoagula- 
tion at the time of events was considered to be etficient 
when the PT was between 15% and 30% and inefficient 
when the PT was greater than 30%; overanticoagulation 
was defined by a PT less than 15%. INR values were 
usually not used at the time under study. 
Statistieal analysis. Fisher's exact test and X 2 test were 
done to detect he univariate risk factors for early death. 
The different late valve-related events were expressed in 
linearized form (percent per patient-year) for which all 
events were considered. Actuarial survival and event-free 
curves were calculated with the Kaplan-Meier method. To 
establish the composite event-free and survival curves, 
valve-related deaths were given precedence over nonfatal 
complications when both occurred. Univariate compari- 
sons of subgroups were made with the log-rank test. The 
list of the screened variables is given in the appendix. 
Cox's proportional-hazards models were then used to 
identify independent prognostic factors. We introduced 
into the models variables having a value of p < 0.1 by 
log-rank test. When some covariates were highly corre- 
lated, we included the most significant one. Results of the 
multivariate analysis are given with estimates of the /3 
coefficient and as odds ratio (95% confidence interval), 
with the significance l vel p value for each variable. 
Results 
In-hospital (<30 days) mortality and complica- 
tions. In  total, there were 54 in-hospita l  events in 50 
pat ients  (15.6% of pat ients) :  10 deaths (3.1% of all 
pat ients;  2.6% with aortic valve rep lacement  [AVR],  
4.2% with mitral  valve rep lacement  [MVR],  3.1% 
with mult ip le  valve rep lacement  [mult ip le VR])  and  
44 nonfata l  events. F i f teen pat ients  (4.7%) died or 
had long- term impa i rment  after the operat ive pe- 
riod. Causes of in-hospita l  deaths and nonfata l  
events are shown in Tab le  V. The  fol lowing risk 
factors for early death were found by univar iate 
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analysis: emergency operation (p < 0.001), New 
York Heart Association (NYHA) class IV symp- 
toms (p = 0.002), additional procedures without 
coronary artery bypass grafting (p -- 0.007), addi- 
tional procedures including coronary artery bypass 
grafting (p = 0.016), concomitant tricuspid anomaly 
(p = 0.025), acute endocarditis (p = 0.041), and 
cardiac index less than 2.5 L/m 2 (p = 0.044). 
Late valve-related events 
Systemic embolism. Forty-six patients had 69 em- 
bolic events (59 cerebral and 10 peripheral) at a 
linearized rate of 2.3%/pt-yr (AVR, 2.0%; MVR, 
2.9%; multiple VR, 2.0%). With three fatal emboli 
the mortality rate was 4% (linearized rate of fatal 
emboli: 0.1%/pt-yr). Fourteen patients had more 
than one embolism, which resulted in a high recur- 
rence rate of 30%. The actuarial probability of 
freedom from embolic events at 5, 10, and 13 years 
for AVR, MVR, and multiple VR is shown in Fig. 1. 
There were no differences among the three groups 
(p = 0.699). Anticoagulation level was known in 47 
events and was insufficient in 32 (PT 31% to 40%, 2; 
PT 41% to 50%, 5; PT 51% to 60%, 7; PT >60%, 
18) and in the target fange in 15. Independent risk 
factors for embolism were eardiac failure and a 
history of prior systemic emboli (Table VI). Atrial 
fibrillation was not a significant risk factor in our 
series. 
Anticoagulation-related hemorrhage. Ninety-nine 
events of anticoagulation-related hemorrhage oc- 
curred in 76 patients (18 cerebral and 81 peripheral) 
at a linearized rate of 3.3%/pt-yr (AVR, 3.6%; 
MVR, 3.4%; multiple VR, 1.7%). Twelve events 
were fatal (mortality rate 12%; linearized rate of 
fatal hemorrhage, 0.4%/pt-yr). Recurrent events 
occurred in 17 patients (recurrence rate 22%). In- 
tracranial hemorrhages are detailed in the next 
section. The gastrointestinal and genitourinary 
tracts were the most common locations of periph- 
eral bleeding (respectively, 39% and 17%). Only two 
patients with peripheral hemorrhage had permanent 
impairment. Overanticoagulation was present in 
only 30 of 56 events (PT <-10%, 20; PT 11% to 14%, 
10). Anticoagulation was in the target range in 18 
and insutticient in 8. Actuarial freedom from hem- 
orrhage at 5, 10, and 13 years is shown in Fig. 2. 
Freedom from hemorrhage t nded to be smaller for 
the AVR group after 96 months, although t e 
difference was not significant for the complete du- 
ration of follow-up (p = 0.365). Univariate analysis 
did not show any risk factor for hemorrhages among 
those listed in the appendix. 
Table V. In-hospital events 
No. 
Deaths 
Valve-related 
Prosthesis disinsertion 1 
Cardiac 7 
Noncardiac 1 
Unknown 1 
Total 10 
Percent of patients 3.1% 
Nonfatal events 
Valve-related 
Cerebral embolism 3 
Systemic embolism 2 
Anticoagulation-related h morrhage 3 
Paravalvular leak 2 
Hemolytic anemia 2 
Cardiac 17 
Surgical 15 
Total 44 
Reoperation 
Paravalvular leak repair 1 
Hemostasis 6 
7 Total 
Cerebrovascular accidents. There were 77 cere- 
brovascular accidents in 54 patients, at a linearized 
rate of 2.6%/pt-yr (AVR, 2.4%; MVR, 3.1%; mul- 
tiple VR, 2.0%). Ischemic accidents represented 59 
events in 42 patients and were recurrent in 12 
(recurrence rate 29%). Of the ischemic erebrovas- 
cular accidents 44% (N = 26) were transient events 
most often diagnosed on a clinical basis; 12% (N = 
7) were reversible neurologic deficits diagnosed 
either by computed tomographic scan (in 5) or 
clinically (in 2); 39% (N = 23) were major strokes, 
and 5% (N = 3) were fatal. Diagnosis was made by 
computed tomographic scan in all but three cases of 
major or fatal strokes. 
Intracranial hemorrhages were less frequent with 
18 events in 14 patients; however, their prognosis 
was more severe with 9 deaths (mortality, 50%) 
because of intracerebral bleeding. Permanent im- 
pairment occurred in 1 case. Seven of the 18 events 
had been associated with recent head trauma. Diag- 
nosis was made by computed tomographic scan in 14 
cases, by lumbar puncture in 1, and clinically in 3. 
Overanticoagulation was documented in 5 of 10 
events. Independent risk factors for all cerebrovas- 
cular accidents were history of systemic emboli, age, 
and cardiac failure (Table VI). When univariate 
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Monds after operation 
Event-free rates: 5 years: AVR: 95.5% -+ 1.6 10 years: AVR: 86.0% -+ 2.9 13 years: AVR: 80.9% + 3.7 
MVR: 92.9% -+ 2.8 MVR: 84.7% + 4.1 MVR: 75.5% + 5.9 
MuVR: 96.6% -+ 3.4 MuVR: 82.7% + 8.0 MuVR: 82.7% _+ 8.0 
All: 94.5% -+ 1.3 All: 85.0% _+ 2.3 All: 79.2% _+ 3.0 
Fig. 1. Actuarial freedom from embolism after AVR, MVR, and multiple VR (MuVR) with standard error 
indicated at 60 and 120 months. Numbers above the time axis indicate the patients at risk at 1, 5, 10, and 
13 years. Differences between groups were not significant. 
Table VL Risk factors for late valve-related events* 
Results of univariate analysis 
by log-rank test 
Cox's proportional hazards model 
(independent risk factors) 
Events Variables p Value Variables [3 OR 95% CI p Value 
Embolism Cardiac failure (CF) 0.024 CF 1.197 3.3 1.3, 8.5 0.013 
History of prior systemic em- 0.046 HSE 1.065 2.9 1.2, 7.0 0.018 
bolism (HSE) 
Postoperative atrial fibrilla- 0.075 
tion 
Cerebrovascular Age ->60 years (AGE) 0.019 HSE 0.998 2.7 1.2, 6.1 0.015 
accidents History of prior systemic ere- 0.034 AGE 0.666 1.9 1.1, 3.4 0.018 
bolism (HSE) 
Cardiac failure (CF) 0.063 CF 0.714 2.0 1.0, 4.1 0.043 
Prosthetic diameter -<23 mm 0.082 
Endocarditis Diabetes (Diab) 0.001 Diab 2.338 10 2.8, 39 <0.001 
Degenerative cause 0.016 OH 1.991 7.3 1.4, 39 0.019 
Alcoholism (OH) 0.026 AVR 2.333 10 1.1, 93 0.038 
Aortic stenosis 0.035 
AVR 0.045 
OR, Odds ratio; CI, confidence interval. 
*Univariate and multivariate analysis. Variables identified by log-rank test with ap < 0.1 were taken for the multivariate analysis. 
analysis was done on the group with intracranial 
hemorrhages only, no risk factor could be identified. 
Actuarial freedom from cerebrovascular ccident 
and intracranial hemorrhage and for the following 
five valve-related complications individually and all 
valve-related events is described in Table VII. 
Prosthesis thrombosis. Four cases of valve throm- 
bosis occurred during the follow-up (linearized rate 
0.1%/pt-yr). There were two cases of partial throm- 
bosis successfully treated by prosthesis replacement, 
one case of complete obstructive fatal thrombosis, 
and one case manifested by a fatal cerebral embo- 
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Months after operation 
Event-free rates: 5 years: AVR: 86.8% + 2.6 10 years: AVR: 71.2% + 3.7 13 years: AVR: 65.3% +_ 4.3 
MVR: 89.0% + 3.5 MVR: 79.2% + 4.7 MVR: 71.0% + 5.7 
MuVR: 92.7% + 5.0 MuVR:83.6% + 7.6 MuVR:76.6% + 9.7 
All: 88.0% + 1.9 All: 74.8% + 2.7 All: 68.1% + 3.2 
Fig. 2. Actuarial freedom from anticoagulation-related hemorrhage after AVR, MVR, and multiple VR 
(MuVR) with standard error indicated at 60 and 120 months. Numbers above the time axis indicate the 
patients at risk at 1, 5, 10, and 13 years. Differences between groups were not significant. 
lism. Three events occurred after AVR (diameter, 
21, 23, and 27 mm) and one after AVR with MVR 
(21 and 31 mm, respectively) in which both valves 
were thrombosed. Insufficient anticoagulation was 
documented at the time of the event and several 
times before in three patients. Anticoagulation was 
adequate on admission to the hospital in the fourth 
but had probably been previously intermittently low 
because two transient ischemic attacks occurred in 
the weeks before the fatal event. 
Endocarditis. Ten patients had 11 events of endo- 
carditis (recurrence rate, 10%); 10 events occurred 
in the AVR group and 1 in the MVR group 
(linearized rate: overall, 0.4%/pt-yr; AVR, 0.6%/pt- 
yr; MVR 0.1%/pt-yr). Two cases were fatal (mortal- 
ity rate, 18%). No survivors needed reoperation. 
Independent risk factors for endocarditis were dia- 
betes mellitus, alcoholism, and AVR (Table VI). 
Prosthesis dysfunction. No case of structural dys- 
function was observed. Paravalvular leak was diag- 
nosed 11 times in 9 patients and led to reoperation 
7 times (recurrence rate, 11%). One case of aortic 
subvalvular stenosis because of fibrosis and muscu- 
lar hypertrophy and one case of incomplete closure 
of an aortic prosthesis because of pannus entrap- 
ment also necessitated reoperation. Eleven aortic 
prostheses and two mitral prostheses were involved 
(linearized rates: for all dysfunctions, 0.4%/pt-yr; 
AVR, 0.6%/pt-yr; MVR 0.2%/pt-yr). The only risk 
factor identified univariately was age 45 years or 
younger (p = 0.030). 
Hemolytic anemia. Four cases of hemolytic ane- 
mia (linearized rate, 0.1%/pt-yr) were diagnosed. 
Three of them were a result of moderate or severe 
paravalvular leak in the aortic position and the condi- 
tion normalized after eoperation. In the fourth case a 
signißcant leak was not found; the anemia was man- 
aged by medical treatment. 
Reoperation. Eleven reoperations were done in 
nine cases (linearized rate: overall, 0.4%/pt-yr, 
AVR, 0.5%/pt-yr; MVR, 0.2%/pt-yr). Paravalvular 
leaks necessitated prosthesis replacement in three 
cases and simple closure of the leak in four. Two 
cases of valve dysfunction and two of valve throm- 
bosis necessitated valve replacement. No significant 
risk factor could be identified. 
Overall valve-related complications. Including all 
fatal and nonfatal emboli, anticoagulation-related 
hemorrhages, prosthetic dysfunctions, hemolytic 
anemias, endocarditis, valve thrombosis, and reop- 
erations, valve-related complications occurred at a 
linearized rate of 7.0%/pt-yr for the whole group 
(AVR, 7.6%; MVR, 6.9%; multiple VR, 4.4%). The 
overall mortality rate for these complications was 
9%. Actuarial estimates are given in Table VII. 
There was no statistical difference between opera- 
1 4 0 Debétaz et al. 
The Journal of Thoracic and 
Cardiovascular Surgery 
January 1997 
Table VII. Actuarial freedom from various valve-related complications at 5, 10, and 13 years 
Percent freedom 
Event Operation 5 yr 10 yr 13 yr 
Cerebrovascular ccident 
Intracranial hemorrhage 
Prosthesis thrombosis 
Endocarditis 
Nonstructural prosthesis dysfunction 
Hemolytic anemia 
Reoperation 
All valve-related events 
AVR 93.6 +- 1.9 81.5 ± 3.2 75.1 -+ 4.1 
MVR 92.8 ± 2.8 83.1 -+ 4.3 77.6 -+ 5.1 
MuVR 96.6 ± 3.4 82.7 -+ 8.0 82.7 ± 8.0 
All 93.4 -+ 1.5 81.8 -+ 2.5 76.5 -+ 3.0 
AVR 97.6 + 1.2 93.9 -+ 2.0 92.3 ± 2.5 
MVR 97.6 -- 1.7 94.8 ± 2.5 94.8 ± 2.5 
MuVR 100 100 100 
All 97.8 ± 0.9 94.8 -+ 1.4 93.9 ± 1.7 
All 98.9 _+ 0.6 98.5 ± 0.7 98.5 ± 0.7 
AVR 99.4 _+ 0.6 95.8 ± 1.7 91.8 ± 2.9 
MVR 98.8 ± 1.2 98.8 _+ 1.2 98.8 ± 1.2 
MuVR 100 100 100 
All 99.3 ± 0.5 97.2 ± 1.1 94.9 ± 1.7 
AVR 97.8 _+ 1.1 96.4 ± 1.5 92.2 ± 3.0 
MVR 98.9 ± 1.1 97.5 ± 1.8 97.5 ± 1.8 
MuVR 100 100 100 
All 98.3 _+ Õ.7 97.1 ± 1.0 94.6 ± 1.8 
All 99.3 ± 0.5 98.5 _+ 0.7 98.5 ± 0.7 
AVR 98.4 ± 0.9 97.0 _+ 1.3 93.6 ± 2.9 
MVR 98.9 ± 1.1 97.5 ± 1.8 97.5 _+ 1.8 
MuVR 100 100 100 
All 98.7 _+ 0.7 97.4 ± 1.0 95.5 ± 1.7 
AVR 86.5 ± 2.6 62.8 ± 3.9 47.4 ± 4.9 
MVR 86.0 ± 3.7 71.2 ± 5.1 56.0 _+ 6.3 
MuVR 89.4 ± 5.8 76.5 ± 8.5 57.7 _+ 10.4 
All 86.3 ± 2.0 66.3 ± 3.0 50.9 ± 3.6 
MuVR, Multiple VR. 
tive groups when the entire follow-up was consid- 
ered (p = 0.502), but beyond 8 years we observed a
trend toward more complications in the AVR 
group. 
Late deaths, overall deaths, and survival. There 
were 125 late deaths during the follow-up at a 
linearized rate of 4.2%/pt-yr (AVR, 4.7%; MVR, 
3.1%; multiple VR, 4.1%). The causes of late death 
are reported in Table VIII. For univariate and 
multivariate analysis we considered early and late 
deaths together (overall mortality), or a total of 135 
deaths. Actuarial survival curves for AVR, MVR, 
and multiple VR are shown in Fig. 3. Predictors of 
mortality identified by univariate and multivariate 
analysis are shown in Table IX. Despite the good 
correlation between mortality and extent of coro- 
nary artery disease (Fig. 4), this was not an indepen- 
dent risk factor when age and cardiac failure were 
considered. Because cardiac index, cardiothoracic 
index, and ejection fraction were measured only in 
subsets of patients, using these factors together in 
the multivariate analysis was not possible and a 
separate Cox's model was defined for each of them. 
Thus independence among these three covariates 
was not tested (the same applied to the multivariate 
analysis for sudden death, valve-related death, and 
cardiac non-valve-related death). Table IX only 
presents the independent risk factors for the model 
including ejection fraction. A high cardiothoracic 
index and a low cardiac index were independent risk 
factors for overall mortality in their respective mod- 
els. Survival in the AVR group tended to be worse 
than that in the MVR group, although this differ- 
ence did not reach significance (p = 0.069). When 
the analysis was done separately for the AVR group, 
the same risk factors for mortality were identified 
univariately. For the MVR group, the risk factors 
identified by log-rank test were coronary artery 
bypass grafting, age 60 years or older, cardiothoracic 
index, emergency operation, NYHA class III or IV, 
alcoholism, diabetes, and presence of cardiovascular 
risk factors. Cardiac index was borderline (p = 
0.061). We did not find in either group a difference 
in survival between stenotic, regurgitant, or mixed 
lesions. 
Sudden death, valve-related, and cardiac non- 
valve-related mortality. Sudden death represented 
an important cause of late deaths (24/125, 19%) in 
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our series (19%, 18%, 25% of late deaths after 
AVR, MVR, multiple VR, respectively; p = 0.565). 
There were 14 men and 10 women with a mean age 
of 62 years who died after a mean of 5.2 years. Nine 
of these patients had coronary disease, 2 had been 
treated for malignant ventricular arrythmias, and 2 
had both diseases. Half of these patients had left 
ventricular hypertrophy and 29% underwent coro- 
nary artery bypass grafting at the time of the valve 
replacement. Comparing the variables listed in the 
appendix between the sudden death group and the 
valve-related death group without sudden death, we 
found that the sudden death group was character- 
ized by a higher mean end-diastolic index (p = 0.02) 
and a higher proportion of patients with ejection 
fraction less than 50% (p = 0.016) whereas ahigher 
proportion of small prostheses (-<23 mm) was found 
in the valve-related eath group. Comparing the 
sudden death group with the group of cardiac 
non-valve-related deaths, we noted only a greater 
frequency of preoperative aortic stenosis in the 
sudden death group (p = 0.04). The risk factors for 
sudden death and cardiac non-valve-related death 
were similar (Table IX). High cardiothoracic index 
and low cardiac index were independent factors for 
cardiac non-valve-related death in their models, and 
the latter was also a risk factor for sudden death. In 
comparison, the prognostic factors for the valve- 
related death group were different (Table IX). Ac- 
marial freedom from valve-related deaths, with and 
without sudden deaths included, is shown in Fig. 5. 
Actuarial freedom rates for sudden death only at 5 
years were 96.6% _+ 1.1%, at 10 years 91.5% + 
1.8%, and at 13 years 91.0% _+ 1.8%. Actuarial 
freedom rates for cardiac non-valve-related death 
only at 5 years were 95.4% _+ 1.2%, at 10 years 
87.3% _+ 2.1%, and at 13 years 81.4% _+ 2.8%. At 
the end of follow-up, 10% of patients in preoper- 
ative NYHA class I, 35% in class II, 48% in class 
III, and 55% in class IV had died after a mean 
survival time of 112, 83, 78, and 56 months, 
respectively. 
Valve-related morbidity and mortality. Fig. 6 
shows the a¢tuarial freedom from fatal and nonfatal 
valve-related complications and from valve-related 
mortality and permanent impairment. Two curves 
are given for each endpoint to take into account the 
inclusion or exclusion of sudden death as a valve- 
related complication. No differences existed among 
the three operative groups for these endpoints. 
Multivariate analysis for each of these combined 
events showed that when sudden death was in- 
Table VllI. Causes of late mortality (125/311 
patients, 40.2%) 
No. of Percent of 
Cause of late death patients late d aths 
Valve-related 19 15 
Cerebral embolism 3 
Intracranial hemorrhage 9 
Gastrointestinal tract hemorrhage 2 
Intrathoracic hemorrhage 1 
Endocarditis 2 
Valve thrombosis 2 
Sudden death 24 19 
Cardiac non-valve-related 39 31 
Cardiac failure 32 
Arrhythmia 4 
Heart grafl rejection 1 
Infarction 2 
Noncardiac 36 29 
Cancer 19 
Infection 8 
Other* 9 
Unknown 7 6 
*Other: 2 ruptured aortic aneurysms, 2 pulmonary emboli, 1 perforated 
gastric ulcer, 1 acute arterial failure in a patient with severe obstructive 
atherosclerosis in both legs, i suicide, 1 renal failure, 1 amyotrophic lateral 
sclerosis. 
cluded, the rate of complications was influenced by 
cardiac failure and coronary artery disease. 
Functional improvement. Ninety percent of the 
survivors were in NYHA class I or II after a mean 
follow-up of 9.5 years in comparison with 43% 
before the valve replacement. The percentage of 
survivors in NYHA class I or II at the end of 
follow-up was 93%, 90%, and 83% for patients in 
preoperative classes I or II, III, and IV, respectively. 
At the end of follow-up 80 patients were not retired. 
The degree of activity was known for 65 of the 
patients: 40 (62%) were working full-time, 10 (15%) 
were partially active, and 15 (23%) were not work- 
ing and received complete disability compensation. 
The reason for complete or partial disability was 
valve-related in 5 cases, cardiac-related in 11, and 
noncardiac in 9. 
Discussion 
The focus of our eomments in this discussion will 
be on particular points coneerning late eomplica- 
tions. 
Embolism. The linearized and actuarial event- 
free rates for embolism are in aecordance with the 
findings of recent studies confirming the low throm- 
bogenicity of this valve. Table X presents the range 
of in¢idence of the usual valve-related end points 
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Fig. 3. Actuarial overall survival after AVR, MVR, and multiple VR (MuVR) with standard error 
indicated at 60 and 120 months. Numbers above the time axis indicate the patients at risk at 1, 5, 10, and 
13 years. Differences between groups were not significant. 
(expressed in linearized form) in 11 of the most 
important follow-up studies on the St. Jude Medical 
valve.* Our data show that embolism is neither the 
most frequent nor the most dangerous valve-related 
complication i  terms of survival. However, it is the 
most recurrent event. Most emboli are related to 
inadequate anticoagulation. This emphasizes the 
need for adequate anticoagulation after valve re- 
placement with the St. Jude Medical prosthesis. 
Atrial fibrillation is not a significant incremental risk 
factor for embolism but is probably partially in- 
volved as shown in a later section of this discussion. 
As also demonstrated by others, 24-26 a history of 
prior embolism is an independent risk factor for 
recurrent events. The reason is not evident, but we 
nevertheless found atrial fibrillation and cardiovas- 
cular risk factors to be more frequent in the group 
with a history of emboli. Cardiac failure as the 
indication for operation is an important risk factor 
because it represents patients with a greater cardio- 
thoracic index, larger atrial diameter, higher NYHA 
class, and more mitral abnormalities. These findings, 
as emphasized by Horstkotte and associates, 27 con- 
firm the need to consider cardiac comorbidity in 
*References 1, 2, 4, 9, 10, 12-15, 17, and 18. 
defining the best range for anticoagulation in indi- 
vidual patients. 
Hemorrhage. Hemorrhage was the most fre- 
quent complication in our series but was without 
permanent consequences in 86% of the cases. The 
link to inadequate anticoagulation is rar less 
evident for hemorrhage than for embolism. The 
rate of hemorrhages in the present report was 
higher than in most comparable studies. The 
disparity in reporting bleeding complications cer- 
tainly accounts for this. Indeed there is a wide 
discrepancy in the published incidence of hemor- 
rhages (and emboli) as shown in Table X, and this 
cannot be attributed only to variations in the 
anticoagulation target range or in the mode of 
control of anticoagulation. Because every bleed- 
ing episode that necessitated hospital care was 
counted (among which many cases were treated 
on an outpatient basis), we certainly included 
more benign events than most reports. Horstkotte 
and associates 27observed in a prospective study a 
linearized rate of 6.7%/pt-yr taking into account 
all benign and severe hemorrhagic events. This 
indicates that rates in retrospective studies are 
probably underestimated (the same conclusion 
applies to embolic events). It has been clear for 
the past few years that the anticoagulation target 
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Table IX. Risk factors for overall mortality, sudden death, valve-related death, and cardiac non-valve-related 
death* 
Results of univariate analysis 
by log-rank test 
Cox's proportional hazards model 
(independent risk factors) 
Event Variables p Value Variables Iß OR 95% CI p Value 
Overall mortality Age -->60 yr (AGE)t <0.001 AGE 0.923 2.5 1.7, 3.8 <0.001 
Presence of coronary diseaset <0.001 EF 0.992 2.7 1.7, 4.2 <0.001 
Severity of coronary disease <0.001 OH 0.817 2.3 1.3, 4.0 0.006 
Cardiothoracic index >0.50 <0.001 HSE 0.865 2.4 1.3, 4.5 0.008 
Ejection fraction <50% (EF)t <0.001 
Cardiac index <2.5 L/m 2 <0.001 
CABG <0.001 
Diabetes reell?tust 0.001 
Alcoholism (OH)t 0.002 
NYHA III-IV versus M i t  0.002 
Presence of CV risk factors 0.012 
Degenerative causet 0.018 
Emergency operationt 0.029 
NYHA IV versus I-III 0.039 
History of systemic embolism (HSE)t 0.049 
MVR versus AVR + multiple VRt$ 0.074 
Syncopet$ 0.082 
Sudden death Severity of coronary disease (SCOR)t 0.001 EF 1.157 3.2 1.2, 8.1 0.016 
Ejection fraction <50% (EF)t 0.001 SCOR 0.457 1.6 1.1, 2.3 0.023 
Presence of CV risk factors 0.011 
CABGt 0.011 
Angor as indication for operation? 0.012 
Presence of coronary disease 0.015 
Alcoholism? 0.016 
Age ->60 yr? 0.042 
Cardiac index <2.5 0.045 
Valve-related death Prosthetic diameter -<23 mm (PDIA)t 0.001 OH 1.540 4.7 1.3, 17 0.018 
Degenerative cause (DC)t 0.001 DC 1.385 4.0 1.2, 13 0.023 
Aortic stenosist 0.021 PDIA 1.062 2.9 1.1, 7.7 0.033 
Diabetes reell?tust 0.041 
Alcoholism (OH)t 0.047 
Age ->60 yrt 0.077 
Cardiac non-valve- Age ->60 yr? 0.001 HSE 1.235 3.4 1.4, 8.6 0.005 
related eath Presence of coronary disease (COR)t 0.001 EF 1.134 3.1 1.5, 6.7 0.007 
Ejection fraction <50% (EF)t 0.002 COR 0.830 2.3 1.1, 4.9 0.012 
CABG 0.008 
Cardiac index <2.5 0.010 
Cardiothoracic index >0.50 0.015 
Pulmonary wedge pressure >20 0.020 
Emergency operationt 0.021 
History of systemic embolism (HSE)t 0.049 
OR, Odds rat?o; C/, confidence interval; CABG, coronary artery bypass grafting; CV, cardiovascular. 
*Univariate and multivariate analysis. 
tIndicates variables entered in the Cox's models. Reasons for excluding variables are given in the paragraphs onstatistics and on late deaths. 
~Indicates variables with a favorable influence on survival. 
for the St. Jude Medical prosthesis should be 
lower than was previously advised to reduce hem- 
orrhages without an increased risk of thromboem- 
boli.lS, 27-28 The recently published guidelines of 
the European Society of Cardiology recommend 
an INR of 2.5 to 3.0 after AVR and 3.0 to 3.5 after 
MVR with the second-generation valves. 29 In other 
respects, hemorrhages seem slightly more frequent in 
the AVR group beyond 9 years (Fig. 2); we do not 
have any satisfactory explanation for that. 
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Cerebrovascular accidents. Eighty-six percent of 
all emboli and 18% of all hemorrhagic events were 
cerebral; the former were lethal in 5% and the latter 
in 50%. Because of the predominance of ischemic 
cerebrovascular ccidents, risk factors for cerebro- 
vascular accidents are similar to those for embolism, 
but age plays a more significant part for cerebrovas- 
cular accidents. 
Other valve-related complications. Out results 
happen to be within the ranges presented in Table 
X. Valve thrombosis is a threatening complication 
with a 50% mortality rate and is strongly linked to 
deficient anticoagulation. Endocarditis is signifi- 
cantly more frequent in patients with diabetes or 
alcoholism or when the underlying valve disease was 
aortic stenosis, particularly that of a degenerative 
cause. Alcoholism, diabetes, and AVR are indepen- 
dent factors. If degenerative disease is a well-known 
risk factor of native valve endocarditis, especially in 
the elderly, to our knowledge it has not been 
described as a persistent risk factor after valve 
replacement. This may be because of the persistence 
or the relapse of calcific depositions and areas of 
epithelial denudation, which promote the develop- 
ment of vegetations. Furthermore, patients in this 
group are older and age is a major risk factor for all 
events. Multiple VR was not associated with an 
increased risk of endocarditis in the present report 
but this remains controversial in the literature. 
Overall mortality and survival. The linearized 
rates of mortality and actuarial survival at 10 years 
are comparable with those given by Ibrahim, 17 
Khan, 13 and Fernandez 12 and their coworkers. Bau- 
det and assoeiates is showed higher survival rates in 
a eomparable sample of patients, but freedom from 
valve-related eath was the same. Horstkotte and 
assoeiates 27also observed a significantly better over- 
all survival at 10 years (AVR, 85%; MVR, 78%; 
double VR, 72%). However, the population was 
different with more female patients, younger pa- 
tients, and a prospective follow-up that could help 
identify complications earlier and contribute to a 
better prognosis. With respect to risk faetors for 
global mortality, coronary artery disease was not 
independent when considered with age and cardiac 
failure. Cardiothoracic index and ejection fraction 
are simple and useful parameters to determine the 
best time for operation and to predict he outcome 
for the patient. Syncope, as an indication for oper- 
ation, has a favorable ffect on late survival; this has 
already been described in previous series of aortic 
stenosis. History of prior systemic emboli was an 
independent risk factor for overall mortality and 
cardiac death; it was not related to an increased 
incidence of fatal cerebral emboli as might be 
expected and, indeed, the first cause of death in this 
subgroup was cardiac failure with no valve-related 
death. Patients with a history of prior emboli show 
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various negative characteristics, ome well known 
(atrial fibrillation, increased risk of atherosclerosis, 
and increased frequency of past cardiac operations) 
and possibly others that are unknown. Eliminating 
this risk factor from the multivariate analysis did not 
make others become significant. In other respects, 
the poorer survival for the AVR group (Fig. 3) was 
somewhat surprising and not in keeping with find- 
ings of most past studies. Only Kratz and col- 
leagues 11 showed similar findings. In the present 
study, this trend was caused by an increased inci- 
dence of various valve-related complications, which 
led to more frequent valve-related deaths, particu- 
larly for degenerative sclerosing valve disease. The 
increased sex ratio; the increased frequency of cor- 
onary artery disease, coronary artery bypass graft- 
ing, and hypertension; and the higher proportion of 
older patients (>70 years) in the AVR group com- 
pared with the MVR and multiple VR groups 
together do not completely explain this point: the 
patient characteristics and the surgical technique 
used for AVR did not differ notably from what has 
previously been reported. Although a selection bias 
cannot be excluded, we perhaps missed some critical 
factors in the history or in the general, cardiac, and 
valvular state of these patients that could explain 
this discrepancy. 
Sudden death and valve-related death. Above 
all, sudden death was linked with a low preoper- 
ative ejection fraction or with coronary artery 
disease, suggesting a non-valve-related cause. We 
agree with Butchart 3° that "it is illogical to at- 
tribute every sudden death in a prosthetic valve 
series to the prosthesis itself, particularly when a 
high proportion of the patients have coronary 
disease"; this realization led us to present out 
data with sudden deaths separately or integrated 
in valve-related eaths. Alcoholism was a risk 
factor for sudden death and for valve-related 
death probably because of anticoagulation-related 
hemorrhages. 
The incidence of valve-related deaths was higher 
with small prostheses (-<23 mm), but small valves 
were used only for aortic replacements, and use of 
small valves was thus a demonstrated risk factor only 
in this category. Small diameter is significantly cor- 
related with female sex, small body surface area, and 
increased age, but this does not fully explain the 
increased risk; the small prostheses may be submit- 
ted to higher forces that lead to paravalvular leaks 
and create turbulences in blood flow that favor 
thrombosis, embolisms, and vegetations. Alcoholism 
and a degenerative cause of valve disease were also 
independent factors of valve-related death but, im- 
portantly, age was not. 
Cardiac non-valve-related eath. Cardiac death 
remained the primary cause of death and was di- 
rectly related to the degree of preoperative coronary 
disease, myocardial dysfunction, and cardiac en- 
largement despite surgical revascularization at the 
time of valve replacement. This emphasizes the 
need for early valvular operation. 
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Table X. Linearized rates (ranges) on valve-related 
complications after valve replacement with St. Jude 
Medical prosthesis in 11 published follow-up studies 
Rate (%/pt-yr) 
Embolism 0.5-3.5 
Hemorrhage 0.1-2.8 
Valve thrombosis 0.0-0.5 
Endocarditis 0.1-0.6 
Paravalvular leaks 0.1-0.8 
Hemolytic anernia 0.0-0.2 
Reoperations 0.1-0.9 
Valve-related deaths 0.5-1.3 
See text for references. 
Funct iona l  improvement .  For survivors the func- 
tional result was excellent and sustained with most 
of patients being in NYHA class I or II after 10 
years. That 77% of the nonretired patients were 
professionally active has, of course, an important 
positive impact in socioeconomic terms. 
L imi ta t ions  o f  the study. Although we tried to 
minimize the effect of the retrospective collection of 
data by a thorough examination of hospital files and 
by precise questionnaires, events such as transient 
ischemic attacks, for example, may be missed and 
information on hemodynamic values and on antico- 
agulation control at the time of events was not 
complete. Differences in the definitions of endpoints 
made comparisons among studies difficult. The 
guidelines of The Society of Thoracic Surgeons and 
The American Association for Thoracic Surgery 
have only partially solved this problem, particularly 
concerning embolic events, valve-related hemor- 
rhages, and sudden death. We used several defini- 
tions in the methods section that may not corre- 
spond to those used in other reports. Statistical 
power, when analyzing covariates in subgroups uch 
as operative groups or types of valvular disease, was 
low because of small numbers of patients or events. 
In conclusion, this study confirms that with St. 
Jude Medical valves, prosthesis-related complica- 
tions are still common and sometimes dangerous. 
About 20% of patients, at 10 years, will be dead of 
valve-related causes or have a permanent impair- 
ment related to the prosthesis. The preoperative 
status of the patients is a major determinant of the 
long-term outcome. Anticoagulätion should be op- 
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t imal  and  adapted to the indiv idual  pat ient  taking 
into account  he var ious risk factors for embol i  and 
hemorrhages.  In  pat ients  wi thout  compl icat ions the 
funct iona l  improvement  is immediate ,  sustained,  
and  warrants  a normal  profess ional  life in the great 
major i ty  of  cases. 
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REFERENCES 
1. Kinsley RH, Antunes MJ, Colsen PR. St. Jude Medical valve 
replaeement: an evaluation of valve performance. J Thorac 
Cardiovasc Surg 1986;92:349-60. 
2. Burckhardt D, Striebel D, Vogt S, et al. Heart valve replace- 
ment with St. Jude Medieal valve prosthesis: long-term 
experience in 743 patients in Switzerland. Circulation 1988; 
78(Suppl):I18-24. 
3. Myers ML, Lawrie GM, Crawford ES, et al. The St. Jude 
valve prosthesis: analysis of the clinical results in 815 implants 
and the need for systemic anticoagulation. J Am Coll Cardiol 
1989;13:57-62. 
4. Arom KV, Nicoloff DM, Kersten TE, Northrup WF, 
Lindsay WG, Emery RW. Ten years' experience with the 
St. Jude Medical valve prosthesis. Ann Thorac Surg 1989; 
47:831-7. 
5. Arom KV, Nicoloff DM, Kersten TE, Northrup WF, 
Lindsay WG, Emery RW. Ten-year follow-up study of 
patients who had double valve replacement with the St. 
Jude Medical prosthesis. J Thorac Cardiovasc Surg 1989; 
98:1008-16. 
6. Nair CK, Mohiuddin SM, Hilleman DE, et al. Ten-year 
results with the St. Jude Medical prosthesis. Am J Cardiol 
1990;65:217-25. 
7. Lund O, Knudsen MA, Pilegaard HK, Magnussen K, Nielsen 
TT. Long-term performance of Starr-Edwards Silastic ball 
valves and St. Jude Medical bi-leaflet valves. Eur Heart J 
1990;11:108-19. 
8. Vogt S, Hoffmann A, Roth J, et al. Heart valve replacement 
with the Björk-Shiley and St. Jude Medical prostheses: a
randomized comparison i  178 patients. Eur Heart J 1990; 
11:583-91. 
9. Czer LSC, Chaux A, Matloff JM, et al. Ten-year experience 
with the St. Jude Medical valve for primary valve replace- 
ment. J Thorac Cardiovasc Surg 1990;100:44-55. 
10. Smith JA, Westlake GW, MuUerworth MH, Skillington PD, 
Tatoulis J. Excellent long-term results of cardiac valve re- 
placement with the St. Jude Medical valve prosthesis. Circu- 
lation 1993;88(pt 2):II49-54. 
11. Kratz JM, Crawford FA, Sade RM, Crumbley AJ, Stroud 
MR. St. Jude prosthesis for aortic and mitral valve replacement: 
a ten-year experience. Ann Thorac Surg 1993;56:462-8. 
12. Fernandez J, Laub GW, Adkins MS, et al. Early and late- 
phase events after valve replacement with the St. Jude 
Medical prosthesis in 1200 patients. J Thorac Cardiovasc 
Surg 1994;107:394-407. 
13. Khan S, Chaux A, Matloff JM, et al. The St. Jude Medical 
valve: experience with 1000 cases. J Thorac Cardiovasc Surg 
1994;108:1010-20. 
14. Nakano K, Koyanagi H, Hashimoto A, et al. Twelve years' 
experience with the St. Jude Medical valve prosthesis. Ann 
Thorac Surg 1994;57:697-702. 
15. Aoyagi S, Oryoji A, Nishi Y, Tanaka K, Kosuga K, Oishi K. 
Long-term results of valve replacement with the St. Jude 
Medical valve. J Thorac Cardiovasc Surg 1994;108:1021-9. 
16. Isomura T, Hisatomi K, Hirano A, Kosuga K, Ohishi K. The 
St. Jude Medical prosthesis in the mitral position. Eur 
J Cardiothorac Surg 1994;8:11-4. 
17. Ibrahim M, O'Kane H, Cleland J, Gladstone D, Sarsam M, 
Patterson C. The St. Jude Medical prosthesis: a thirteen- 
year experience. J Thorac Cardiovasc Surg 1994;108:221- 
30. 
18. Baudet EM, Puel V, McBride JT, et al. Long-term results of 
valve replacement with the St. Jude Medical prosthesis. J 
Thorac Cardiovasc Surg 1995;109:858-70. 
19. Hjelms E. Escape of a leaflet from a St. Jude Medical 
prosthesis n the mitral position. J Thorac Cardiovase Surg 
1983;31:310-2. 
20. Ziemer G, Luhmer I, Oelert H, Borst HG. Malfunction of a 
St. Jude Medical heart valve in mitral position. Ann Thorac 
Surg 1982;33:391-4. 
21. Edmunds LH, Clark RE, Cohn LH, Miller DC, Weisel RD. 
Guidelines for reporting morbidity and mortality after 
cardiac valvular operations. Ann Thorac Surg 1988;46: 
257-9. 
22. Bodnar E, Butchart EG, Bamford J, Besselaar AMPH, 
Grunkemeier GL, Frater RWM. Proposal for reporting 
thrombosis, embolism and bleeding after heart valve replace- 
ment. J Heart Valve Dis 1994;3:120-3. 
23. McGoon DC. The risk of thromboembolism following valvu- 
lar operations: How does one know? J Thorac Cardiovasc 
Surg 1984;88:782-6. 
24. Mitchell RS, Miller DC, Stinson EB, et al. Significant patient- 
related determinants of prosthetic valve performance. J 
Thorac Cardiovasc Surg 1986;91:807-17. 
25. Lindblom D. Long-term clinical results after mitral valve 
replacement with the Björk-Shiley prosthesis. J Thorac Car- 
diovasc Surg 1988;95:321-33. 
26. Eberlein U, von der Emde J, Rein J, Esperer HD. Throm- 
boembolic and bleeding complications after mitral valve 
replaeement. Eur J Cardiothorac Surg 1990;4:605-12. 
27. Horstkotte D, Schulte HD, Bircks W, Strauer B. Unexpected 
findings eoncerning thromboembolic complications and anti- 
coagulation after complete 10 year follow-up of patients with 
St. Jude Medical prostheses. J Heart Valve Dis 1993;2:291- 
301. 
28. Kopf GS, Hammond GL, Geha AS, Elefteriades J, Hashim 
SW. Long-term performance of the St. Jude Medical valve: 
low incidence of thromboembolism and hemorrhagic compli- 
cations with modest doses of warfarin. Circulation 1987; 
76(Suppl):III132-6. 
29. Gohlke-Bärwolf C, Acar J, Oakley C, et al. Study group of 
the working roup on valvular heart disease of the European 
Society of Cardiology: guidelines for prevention of thrombo- 
embolic events in valvular heart disease. Eur Heart J 1995; 
16:1320-30. 
30. Butchart EG. The significanee of sudden and unwitnessed 
death after heart valve replacement. J Heart Valve Dis 
1994;3:1-4. 
1 4 8 'Debétaz et al. 
The Journal of Thoracic and 
Cardiovascular Surgery 
January 1997 
Appendix 
The following table shows the risk factors screened by 
log-rank test for each valve-related complication, for 
overall mortality, for valve-related death, sudden death, 
cardiac non-valve-related eath, and for combined 
events (mortality and morbidity, mortality and perma- 
nent morbidity) with and without sudden death in- 
cluded. After this first screening, we tested, when 
needed, one or more specific physiopathologic anoma- 
lies against the others. The same was done for the 
different causes of valve disease or for the distinct 
groups of valvular replacement. 
Variables Categories 
Sex 
History of prior cardiac operation 
History of prior embolism 
Diabetes before operation 
Presence of cardiovascular risk factors 
Presence of coronary disease* 
Severity of coronary disease¢ 
Coronary arterial bypass grafting additional 
to the valvular eplacement 
Other additional procedures 
Chronic alcohol abuse before operation 
Emergency operation 
Cardiac rhythm before operation 
Cardiac rhythm, end of hospitalization:~ 
Physiopathologic anomaly (for single valve 
replacement only) 
Cause of valve disease 
Associated tricuspid valvulopathy (structural 
or functional, operated or not) 
Cardiac failure as single indication for oper- 
ation 
Syncope as single indication for operation 
Angor as single indication for operation 
Acute preoperative bacterial endocarditis 
NYHA class 
Operation 
Age (yr) 
Cardiothoracic ndex 
Ejection fraction (%) 
Cardiac index (L/min/m 2) 
Left ventricular end-diastolie ndex (ml/m 2) 
Left ventricular end-systolic index (ml/m 2) 
Mean pulmonary arterial pressure (mm Hg) 
Pulmonary wedge pressure (mm Hg) 
Prosthesis diameter (mm) 
Male/female 
Absent/present 
Absent/present 
Absent/present 
Yes/no 
Absent/present 
Absent/monotruncal/bitruncalAritruncal or common trunk 
Absent/present 
Absent/present 
Absent/present 
Yes/no 
Sinusal/atrial fibrillation 
Sinusal/atrial fibrillation 
Mitral regurgitation/mitral stenosis/mixed mitral disease/aortic 
regurgitation/aortic stenosis/mixed aortic disease 
Rheumatic/congenital/endocarditic/degenerative/myxomatous/ 
prosthetic dysfunction/ischemic/aortic root disease 
Absent/present 
Ye«no 
Yes/no 
Yes/no 
Yes/no 
NYHA I-II/NYHA III-IV and NYHA I-III/NYHA IV 
AVR/MVR/multiple VR 
<45/->45 and <60/->60 
---0.50/>0.50 
<50/->50 
<2.5/->2.5 
<100/->100 
<45/->45 
<30/->30 
<20/_>20 
-<23/>23 and <27/->27 
*The presence orabsence ofcoronary disease was defined by history of prior myocardial infarction or prior coronary artery bypass grafting or by the presence 
of significant (>50%) stenosis of a major coronary artery on the preoperative arteriogram. 
¢Severity of coronary disease: only patients with preoperative coronary disease were considered to do the classification into monotruncal/bitruncal/tritruncaI. 
Only stenoses ofmore than 50% were considered. 
:~This variable was not used to analyze endpoints including in-hospital events (such as overall mortality). 
